Clostridium difficile - adjuvant therapy with high dose VSL#3® will shorten hospital stay and reduce relapse rates in Clostridium difficile associated diarrhoea

Not Applicable

Completed

• Conditions: Clostridium difficile associated diarrhoea; Digestive System; Diarrhoea

• Registration Number: ISRCTN57305201
• Lead Sponsor: niversity Hospitals Bristol NHS Foundation Trust (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2008-02-13
• Last Update Posted: 17 October 2016

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 114

Inclusion Criteria

Any consenting adult patient over the age of 18 years admitted to a Clostridium difficile Cohort Ward in either Gloucester Royal Hospital or Cheltenham General Hospital. Male and female genders will be included.

Exclusion Criteria

There is no upper age limit and patients with IBD will not be excluded. Apart from this, the following patients will be excluded:
1. Those with evidence of dilated colon on plain abdominal film on admission
2. Any patient known to be immunosuppressed (including those on steroids)
3. Any patient refusing the VSL#3® as part of their treatment regime
4. Patients with lactose intolerance or allergy
5. Any patient with a history of rheumatic heart disease or prosthetic heart valve
6. Any patient with a history of endocarditis

Study & Design

• Study Type: Interventional
• Study Design: Not specified